About Us

About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agitation in Alzheimer's Disease Market Research Report 2025-2035, Competitive Profiles of Otsuka Pharmaceutical, Lundbeck, Axsome Therapeutics, and BioXcel - ResearchAndMarkets.com

By: via Business Wire

The "Agitation in Alzheimer's Disease Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.

The market for pharmaceutical treatments addressing agitation in Alzheimer's disease is driven by several key factors, including the growing prevalence of Alzheimer's disease, the aging global population, and the rising recognition of the impact of agitation on patient and caregiver well-being.

Traditional management of agitation in Alzheimer's disease primarily relied on antipsychotic drugs, but these treatments come with significant side effects and limited efficacy. As a result, there has been a shift toward developing targeted therapies that aim to specifically address agitation while minimizing adverse effects. New drug classes, such as beta-adrenergic antagonists, NMDA receptor antagonists, and serotonergic modulators, are emerging as potential therapies for agitation in Alzheimer's disease, offering more focused and effective treatment options.

One of the main drivers for the agitation in the Alzheimer's disease market is the rising number of Alzheimer's disease patients globally. As the prevalence of Alzheimer's disease continues to increase, particularly in aging populations, the demand for treatments that address the behavioral and psychological symptoms, including agitation, is growing. Agitation is a critical concern for caregivers, as it leads to increased caregiver burden, hospitalizations, and long-term institutional care. Effective pharmacological interventions that can manage agitation symptoms are expected to improve patient care and reduce overall healthcare costs, creating significant opportunities for pharmaceutical companies.

Additionally, advancements in drug development and the increasing focus on precision medicine are accelerating market growth. Companies such as Otsuka Pharmaceuticals are developing novel therapeutics that target the underlying mechanisms of agitation, including drugs that modulate neurotransmitter systems or alter brain activity. These innovative therapies aim to offer more precise, effective, and safer solutions compared to traditional antipsychotic drugs. Furthermore, advancements in biomarker discovery and early diagnosis are enabling better identification of patients who may benefit from agitation-specific treatments, enhancing the potential for drug efficacy and improved patient outcomes.

Despite the promising growth in the agitation in the Alzheimer's disease market, several challenges remain. The high cost of developing and manufacturing novel therapies, combined with regulatory hurdles, can delay market entry for new treatments. Additionally, concerns about the safety profiles of drugs for agitation, particularly long-term use, persist. Many of the newer drugs in development are focused on minimizing the side effects seen with older antipsychotics, but the lack of long-term data on their safety could hinder physician adoption. Nonetheless, the continued focus on targeted pharmacological interventions and the development of more personalized treatment plans offers significant growth potential in this therapeutic area, improving the management of agitation in Alzheimer's disease and enhancing the quality of life for both patients and caregivers.

Key players in the agitation in the Alzheimer's disease treatment market are adopting innovative strategies to gain a competitive edge. Companies are focusing on gene therapies to provide long-term solutions for managing agitation. Their approach targets underlying neurobiological processes to reduce agitation episodes, positioning the company as a leader in personalized therapy for neurodegenerative diseases. Otsuka Pharmaceuticals is exploring serotonergic modulation, developing drugs that influence serotonin receptors to calm agitation and improve cognitive function. This strategy offers safer alternatives to traditional antipsychotics, aiming to minimize side effects while enhancing patient outcomes.

Companies are investing heavily in biomarker-driven research, tailoring treatments to patients' genetic profiles to improve the precision and efficacy of agitation management. By integrating biomarkers into their development process, they aim to reduce treatment risks and improve outcomes. Moreover, these companies are advancing combination therapies that address both agitation and cognitive decline, offering a holistic approach to Alzheimer's disease treatment. These strategies reflect a broader shift towards more targeted, integrated, and patient-centric approaches in the market.

The agitation in Alzheimer's disease market is experiencing significant growth, driven by several key trends. A major development is the emergence of targeted therapies, and increasing focus on non-pharmacological interventions. Techniques such as music therapy, aromatherapy, and structured routines are gaining popularity as complementary treatments to reduce the reliance on traditional pharmacological therapies, particularly antipsychotics, which are associated with risks like sedation and metabolic side effects. Moreover, integrated care models that emphasize multidisciplinary support for both patients and caregivers are emerging as essential components of comprehensive treatment plans. This holistic approach not only addresses the immediate symptoms of agitation but also supports the long-term well-being of patients.

Additionally, recent regulatory and pipeline advancements underscore the growing recognition of agitation as a critical symptom of Alzheimer's disease. The FDA's priority review of aripiprazole by Otsuka Pharmaceuticals in 2023 highlights the increasing focus on developing effective treatments for agitation. Furthermore, gene therapies and anti-tau antibodies are progressing into early-stage trials, marking a shift towards disease-modifying therapies that go beyond amyloid-beta targeting. These advancements signal a broader movement in the market towards more innovative, targeted, and multifaceted treatment approaches to address agitation in Alzheimer's disease.

Key Topics Covered:

1. Global Agitation in Alzheimer's Disease Market: Industry Outlook

1.1 Market Overview

1.2 Epidemiological Analysis of Agitation in Alzheimer's Disease, By Region

1.3 Regulatory Landscape of Agitation in Alzheimer's Disease Market

1.3.1 Legal Requirement and Framework in the U.S.

1.3.2 Legal Requirement and Framework in the E.U.

1.3.3 Legal Requirement and Framework in Japan

1.4 Key Trends

1.5 Clinical Trial Analysis

1.6 Market Dynamics

1.6.1 Impact Analysis

1.6.2 Market Drivers

1.6.3 Market Restraint

1.6.4 Market Opportunities

2. Global Agitation in Alzheimer's Disease Market, by Region, $Million, 2023-2035

2.1 North America

2.1.1 Key Market Participants in North America

2.1.2 Market Dynamics

2.1.3 Market Sizing and Forecast

2.1.3.1 North America Agitation in Alzheimer's Disease Market, by Country

2.1.3.1.1 U.S.

2.2 Europe

2.2.1 Key Market Participants in Europe

2.2.2 Market Dynamics

2.2.3 Market Sizing and Forecast

2.2.3.1 Europe Agitation in Alzheimer's Disease Market, by Country

2.2.3.1.1 Germany

2.2.3.1.2 U.K.

2.2.3.1.3 France

2.2.3.1.4 Italy

2.2.3.1.5 Spain

2.3 Asia-Pacific

2.3.1 Key Market Participants in Asia-Pacific

2.3.2 Market Dynamics

2.3.3 Market Sizing and Forecast

2.3.3.1 Asia-Pacific Agitation in Alzheimer's Disease Market, by Country

2.3.3.1.1 Japan

3. Global Agitation in Alzheimer's Disease Market: Competitive Landscape and Company Profiles

3.1 Competitive Landscape

3.1.1 Key Developments and Strategies

3.1.1.1 Funding Activities

3.1.1.2 Mergers and Acquisitions

3.1.1.3 Regulatory Approvals

3.1.1.4 Partnerships, Collaborations and Business Expansions

3.2 Company Profiles

3.2.1 Overview

3.2.2 Product Portfolio

3.2.3 Target Customers

3.2.4 Key Personnel

3.2.5 Analyst View

  • Otsuka Pharmaceutical, Inc.
  • Lundbeck
  • Axsome Therapeutics
  • BioXcel

For more information about this report visit https://www.researchandmarkets.com/r/s40z73

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com



For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

More News

View More
Cybersecurity Market Set to Double: This ETF Offers Exposure
Via MarketBeat
Topics Artificial Intelligence Credit Cards ETFs
Tickers BUG CRWD CYBR PANW VRNS ZS
Downgraded But Not Done: 3 Stocks Ready for a Market Comeback
Via MarketBeat
Topics Artificial Intelligence
Tickers CRM CRWD FTNT
Solana Beat BTC and ETH in Q3: These 3 Stocks Saw It Coming
Via MarketBeat
Topics ETFs
Tickers DFDV F FORD JNVR MSTR UPXI
Ford Set to Outpace GM With Tariff Tailwinds and EPS Momentum
Via MarketBeat
Topics World Trade
Tickers F GM TSLA
Replace Your Fixed Income With This Dividend ETF
Via MarketBeat
Topics ETFs Economy
Tickers AMZN JEPI META NVDA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.